**United Therapeutics Reports Increased Revenue Driven by Tyvaso Sales**

United Therapeutics Corporation (UTHR) reported total revenues of $3.18 billion for the year ended December 31, 2025, an 11% increase compared to $2.88 billion in 2024. This growth was primarily fueled by a 16% rise in combined Tyvaso DPI and Nebulized Tyvaso net product sales, reaching $1.88 billion, representing 59% of total revenues. Remodulin net product sales decreased slightly by 2% to $526.8 million, while Orenitram net product sales increased by 14% to $496.9 million. Unituxin net product sales decreased by 5% to $226.8 million, and Adcirca net product sales increased by 26% to $30.0 million.

The company's financial performance also saw an increase in net income, which rose to $1.33 billion in 2025 from $1.20 billion in 2024. Research and development expenses increased by 14% to $550.0 million, reflecting ongoing investments in pipeline programs such as the TETON studies for Nebulized Tyvaso in IPF and PPF, and the ADVANCE OUTCOMES study for Ralinepag in PAH. Selling, general, and administrative expenses also increased by 6% to $755.8 million, primarily due to higher personnel and legal expenses.

Operationally, United Therapeutics achieved several milestones, including the FDA clearance of its Investigational New Drug application (IND) for the EXPAND study of its UKidney product and the submission of an IND for the EXTEND clinical study of its UThymoKidney product. The company also completed the acquisition of IVIVA Medical, Inc., focused on bio-artificial manufactured kidney alternative products. The first transplant in the EXPAND study occurred in the fourth quarter of 2025, and the study is ongoing.

Looking ahead, United Therapeutics expects revenue growth to be driven by continued sales of Tyvaso DPI, increased adoption of Tyvaso DPI and Nebulized Tyvaso in PH-ILD patients, and growth in Orenitram prescriptions. The company anticipates releasing topline data from the ADVANCE OUTCOMES study of Ralinepag late in the first quarter or early in the second quarter of 2026. United Therapeutics plans to develop an oral triple-combination therapy consisting of Ralinepag, an endothelin receptor antagonist, and a PDE-5 inhibitor, assuming the ADVANCE OUTCOMES study is successful. The company has budgeted approximately $400 million for capital expenditures through the end of 2028 to construct additional facilities to support the development and commercialization of its products and technologies.

About UNITED THERAPEUTICS Corp

United Therapeutics is a biotech company focused on developing therapies for pulmonary arterial hypertension and other life-threatening diseases. It markets inhaled, injectable, and oral medications, and is pioneering organ manufacturing, xenotransplantation, and regenerative medicine to address organ shortages. Its core value lies in innovative treatments, advanced organ technologies, and sustainable delivery solutions, serving global markets with a focus on rare and severe conditions.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.